Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Auto-crosslinked hyaluronic acid (ACP) is a bioresorbable gel composed of hyaluronic acid that has undergone an internal esterification process to create cross-links between polymer chains without the use of foreign chemical agents. This modification enhances the gel's viscosity and persistence at the site of application compared to natural hyaluronic acid. ACP is primarily utilized as a surgical adjuvant to prevent postoperative adhesions, particularly in gynecological and abdominal surgeries. By providing a temporary physical barrier between traumatized tissue surfaces during the healing process, it prevents the formation of fibrin bridges and subsequent permanent adhesions. It is commonly marketed under the brand name Hyalobarrier for the prevention of intrauterine adhesions following procedures such as hysteroscopic adhesiolysis or dilatation and curettage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on auto-crosslinked hyaluronic acid.